 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Comparison of Two Forms of the Anticlotting Drug Heparin for Treatment of Blood Clots in the Legs
6 February 2001 | Volume 134 Issue 3 | Page S76
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician.
The summary below is from the full report titled "Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease." It is in the 6 February 2001 issue of Annals of Internal Medicine (volume 134, pages 191-202). The authors are G Merli, TE Spiro, C-G Olsson, U Abildgaard, BL Davidson, A Eldor, D Elias, A Grigg, D Musset, GM Rodgers, AA Trowbridge, RD Yusen, and K Zawilska, for the Enoxaparin Clinical Trial Group.
What is the problem and what is known about it so far?
Deep venous thrombosis (DVT) is a condition in which blood clots form in the large leg veins, causing pain and swelling. It is important to treat DVT because clots can break off and travel through the bloodstream to the lungs, a potentially deadly condition called pulmonary embolism. DVT is most commonly treated with blood thinners, usually starting with standard heparin given intravenously (through a small tube inserted into a vein) for 5 to 10 days, followed by warfarin, a pill that is generally taken for at least 3 months. A new type of blood thinner called low-molecular-weight heparin has recently become available. Treatment with low-molecular-weight heparin is more convenient since it can simply be injected under the skin once or twice a day. In addition, unlike patients receiving standard heparin, patients receiving low-molecular-weight heparin do not need frequent blood tests to guide dose changes. Several studies have suggested that low-molecular-weight heparin is an effective treatment for DVT. However, those studies were small, did not include patients who had DVT plus pulmonary embolism, and used two injections per day rather than one.
Why did the researchers do this particular study?
To find out whether once-a-day injections of enoxaparin (a particular type of low-molecular-weight heparin) were as effective in the treatment of DVT (with or without pulmonary embolism) as intravenous heparin or twice-a-day injections of enoxaparin.
Who was studied?
The study included 900 patients with DVT cared for at 74 hospitals in 16 countries. Of the 900 patients, 287 also had pulmonary embolism.
How was the study done?
As soon as DVT was diagnosed, patients were randomly assigned to receive either standard heparin intravenously, two 1-milligram injections of enoxaparin per day, or one 1.5-milligram injection of enoxaparin per day. Patients also began taking oral blood thinners within 72 hours of entering the study.
What did the researchers find?
Symptoms of DVT returned with equal frequency in the three treatment groups; no difference was noted in the frequency of bleeding complications with the three types of treatment.
What were the limitations of the study?
Some patients with DVT would have been too sick to be eligible for the study, so it is unclear whether these results would apply to all patients with this condition. Of the 900 patients, only 740 completed enough of the study to be included in the analysis.
What are the implications of the study?
In the treatment of DVT (with or without pulmonary embolism), injection of enoxaparin once or twice daily appears to be as effective as intravenous heparin and does not cause more bleeding complications.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Phillips, P. P. Dobesh, and S. T. Haines Considerations in using anticoagulant therapy in special patient populations Am. J. Health Syst. Pharm., August 1, 2008; 65(15_Supplement_7): S13 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. T. Shih and M. T. Halpern Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Groce Initial management of deep venous thrombosis in the outpatient setting Am. J. Health Syst. Pharm., May 1, 2008; 65(9): 866 - 874. [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Tapson Acute Pulmonary Embolism N. Engl. J. Med., March 6, 2008; 358(10): 1037 - 1052. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sari and V. Davutoglu Enoxaparin-Induced Reversible Pancytopenia Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 453 - 454. [PDF]
|
|
|
|
|
|
T. A. Morris, S. Castrejon, G. Devendra, and A. C. Gamst No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis Chest, October 1, 2007; 132(4): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Umscheid, R. Agarwal, and G. Gibson Weight-Based Low-Molecular-Weight Heparin versus Weight-Based Intravenous Unfractionated Heparin Ann Intern Med, September 18, 2007; 147(6): 433 - 434. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Nutescu Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches Am. J. Health Syst. Pharm., June 1, 2007; 64(11_Supplement_7): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Krivak and K. K. Zorn Venous Thromboembolism in Obstetrics and Gynecology Obstet. Gynecol., March 1, 2007; 109(3): 761 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Deitcher, C. M. Kessler, G. Merli, J. R. Rigas, R. M. Lyons, and J. Fareed Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 389 - 396. [Abstract] [PDF]
|
|
|
|
 |
|
 E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mismetti, S. Quenet, M. Levine, G. Merli, H. Decousus, E. Derobert, and S. Laporte Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism: An Individual Patient Data Meta-analysis Chest, October 1, 2005; 128(4): 2203 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. Jones, J. B. Muhlestein, K. W. Jones, D. G. Renlund, T. L. Bair, T. J. Bunch, B. D. Horne, D. L. Lappe, J. L. Anderson, and D. B. Doty Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated with Increased Surgical Re-Exploration for Bleeding Ann. Thorac. Surg., August 1, 2005; 80(2): 518 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Haines and E. A. Nutescu Current and emerging treatment options for venous thrombosis: A case discussion Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 593 - 605. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-N. Fiessinger, M. V. Huisman, B. L. Davidson, H. Bounameaux, C. W. Francis, H. Eriksson, T. Lundstrom, S. D. Berkowitz, P. Nystrom, M. Thorsen, et al. Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial JAMA, February 9, 2005; 293(6): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]
|
|
|
|
|
|
J. Hirsh and R. Raschke Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 188S - 203S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Buller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 401S - 428S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. McRae and J. S. Ginsberg Initial Treatment of Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-3 - I-9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon Long-Term Management of Patients After Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-10 - I-18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Buller, B. L. Davidson, H. Decousus, A. Gallus, M. Gent, F. Piovella, M. H. Prins, G. Raskob, A. E.M. Segers, R. Cariou, et al. Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial Ann Intern Med, June 1, 2004; 140(11): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Quinlan, A. McQuillan, and J. W. Eikelboom Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials Ann Intern Med, February 3, 2004; 140(3): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Matisse Investigators Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism N. Engl. J. Med., October 30, 2003; 349(18): 1695 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Superficial Thrombophlebitis Treated by Enoxap A Pilot Randomized Double-blind Comparison of a Low-Molecular-Weight Heparin, a Nonsteroidal Anti-inflammatory Agent, and Placebo in the Treatment of Superficial Vein Thrombosis Arch Intern Med, July 28, 2003; 163(14): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax, June 1, 2003; 58(6): 470 - 483. [Full Text] [PDF]
|
|
|
|
|
|
R. Raschke, J. Hirsh, and J. R. Guidry Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin Ann Intern Med, May 6, 2003; 138(9): 720 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Lucey and C. A. Cole Update in General Internal Medicine Ann Intern Med, September 3, 2002; 137(5_Part_1): 334 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
 |
|
 Enoxaparin Effective for DVT Journal Watch (General), March 2, 2001; 2001(302): 2 - 2. [Full Text]
|
|
|
|
 |
|
 J. A. Ginsberg, M. A. Crowther, R. H. White, and T. L. Ortel Anticoagulation Therapy Hematology, January 1, 2001; 2001(1): 339 - 357. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
